JAMA Network
About The Study: Among outpatients with mild to moderate COVID-19, treatment with 50 mg of fluvoxamine twice daily for 10 days, compared with placebo, did not improve time to sustained recovery in this randomized clinical trial that included 1,288 adults. These findings do not support the use of fluvoxamine at this dose and duration in patients with mild to moderate COVID-19.
Authors: Susanna Naggie, M.D., M.H.S., of Duke University in Durham, North Carolina, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2022.24100)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
